Categories AlphaGraphs, Analysis, Technology

Salesforce stock slumps on weak outlook despite upbeat Q4 earnings

Stock-trend disruptor Salesforce (CRM) posted its fourth-quarter earnings on March 4, Monday, after the closing bell.

Total quarterly revenue jumped 26% to $3.60 billion. Earnings was 46 cents per diluted share, while non-GAAP diluted earnings was $0.70 a share.

While many are of the opinion that the stock is overvalued, the market touted Salesforce to earn 55 cents a share on revenue of about $3.5 billion. This is almost 25% higher top-line than a year ago.

Image courtesy: Salesforce UK

Unearned revenue on the balance sheet as of January 31, 2019 was $8.56 billion, up 22% year-over-year. For the year, revenue grew 26% to $13.28 billion, generating earnings of $1.43 per diluted share.

“This is just the beginning, which is why we’re now targeting $26 to $28 billion in revenue by FY23 – organically doubling our revenue again in the next four years,” said Salesforce co-CEO Keith Block.

Salesforce Q4 2019 earnings infographic

LOOKING FORWARD

In the upcoming first-quarter of fiscal 2020, Salesforce sees quarterly revenue grow about 22% to hit $3.67-3.68 billion, generating GAAP EPS of $0.10-0.11 and Non-GAAP EPS of $0.60-0.61.

For the fiscal year 2020, the company touts revenue to jump 20-21% and reach between $15.95 and $16.05 billion. Salesforce expects to earn 66 to 68 cents per share on a GAAP basis, and $2.74-2.76 per adjusted share.

Despite top-line and bottom-line results beating the Street consensus, the stock fell in after-market trade as investors did not take kindly to the tepid outlook.

 

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Comments

  1. Pingback: glaceau
  2. Pingback: cz bren 2
  3. Pingback: 5.56 green tips
  4. Pingback: business in canada
  5. Pingback: Cake carts
  6. Pingback: scrap car pickup
  7. Pingback: BERETTA 92FS
  8. Pingback: Weed Delivery
  9. Pingback: Takeaway
  10. Pingback: penis extender
  11. Pingback: zwitsal
  12. Pingback: Google
  13. Pingback: Payday Loans
  14. Pingback: listen here
  15. Pingback: Haupia strain
  16. Pingback: Watermelon haupia
  17. Pingback: Watermelon haupia
  18. Pingback: Bubble hash
  19. Pingback: Moroccan hash
  20. Pingback: Litto
  21. Pingback: Bubble hash
  22. Pingback: bahis siteleri
  23. Pingback: 1courtesy
  24. Pingback: University of Embu
  25. Pingback: A片
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top